Cabenuva is ViiV Healthcare’s first long-acting injectable and combines the integrase strand transfer inhibitor (INSTI) cabotegravir, with the non-nucleoside reverse transcriptase inhibitor (NNRTI) rilpivirine.

Cabenuva was approved by Health Canada on 18 March 2020 and by the US Food and Drug Administration on 21 January 2021. It is the first and only complete long-acting regimen for the treatment of HIV-1 infection in adults to replace the current antiretroviral regimen in those who are virologically stable and suppressed (HIV-1 RNA less than 50 copies per milliliter [mL]).1,2

Cabenuva is currently under review by other global regulatory authorities.

[1] Cabenuva (cabotegravir/rilpivirine) Product Monograph Canada.

[2] Cabenuva (cabotegravir, rilpivirine) Prescribing Information. US Approval 2021.

Prescribing Information


Product Monograph for Cabenuva

Monographie de Cabenuva

United States

Prescribing Information and Patient Information for Cabenuva